PeerVoice Clinical Pharmacology Audio

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy

Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice

Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves